GlassScriptPhysician profile
Selina Singh Hamill
NPI 1124462577
$9,747.35
in general payments reported to CMS, 2019-2025
30 companies · $2,157 in 2025
The $2,157 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $75.89 · 2021: $1,004 · 2022: $1,632 · 2023: $2,467 · 2024: $2,099 · 2025: $2,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,722.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.01 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $951.62 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $732.49 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $706.22 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $670.19 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $669.04 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $568.91 | 2021-2025 | Dupixent |
| Incyte Corporation | $537.86 | 2021-2025 | Opzelura |
| Genzyme Corporation | $527.71 | 2021-2025 | |
| Dermavant Sciences, INC. | $491.61 | 2022-2024 | Vtama |
| Lilly USA, LLC | $476.58 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $471.48 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $438.09 | 2020-2025 | Tremfya, Remicade, Simponi Aria |
| Ucb, INC. | $314.06 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $162.69 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $149.53 | 2021-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $139.82 | 2019-2024 | Cabtreo, Jublia, Targretin |
| Organon LLC | $74.55 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.99 | 2024 | Spevigo |
| Celgene Corporation | $49.15 | 2019 | |
| Biofrontera INC. | $45.10 | 2019-2020 | |
| Revance Therapeutics, INC. | $34.89 | 2024 | Daxxify |
| Medline Industries LP | $29.07 | 2022 | |
| Sandoz INC. | $28.52 | 2023-2024 | Hyrimoz |
| Kerecis Limited | $24.60 | 2021 | |
| Strata Skin Sciences, INC. | $22.25 | 2022 | |
| Allergan, INC. | $21.57 | 2021 | |
| Fidia Pharma USA INC. | $19.30 | 2025 | |
| Botanix Sb INC | $16.66 | 2025 | Sofdra |
| Merz North America, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selina Hamill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.